Building a path to GMP
Using Cas9 in protein form provides many benefits, including reduced off-target effects, immediate activity (no need to transcribe and/or translate) and controlled dosage. Aldevron gene editing nucleases are available in defined formulations and can be custom-manufactured to meet your specific needs. Our enzymes are engineered to be used in a variety of applications including electroporation, transfection and microinjection.
To simplify the sourcing process for our clients, Aldevron provides a one-vendor strategy for both pre-clinical and GMP gene editing nucleases. Aldevron's gene editing enzymes are described below:
SpyFiTM Cas9 Nuclease: Reduced off-target activity without loss of editing efficiency
From basic research to clinical applications, our new SpyFi Cas9 Nuclease delivers greater editing efficiency, higher fidelity and reduced off-target activity to help accelerate your CRISPR-Cas9 gene editing program. Currently available at research grade, Aldevron also plans to launch GMP grade SpyFi Cas9 Nuclease. The chart below shows how Aldevron’s SpyFi Cas9 Nuclease yields undetectable off-target cutting across four different protein dosages.
Aldevron’s SpyFi Cas9 Nuclease is sold under license of patents and/or patents pending from Integrated DNA Technologies, Inc. (IDT). The SpyFi Cas9 Nuclease data shown above was generated in collaboration with IDT.
GMP sNLS-SpCas9-sNLS Nuclease: A simple solution from R&D to Clinical Material
Aldevron provides research grade Cas9 nucleases for use in development work as well as a standard GMP product for clinical studies. Our GMP Cas9 is dispensed in 10 and 50 mg pack sizes. The construct design is shown below.